# How Far You Can Walk

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/how-far-you-can-walk

> Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

## Key points

- A FUNCTIONAL endpoint: treadmill distance before leg pain stops you, not a lab value.
- 13% further than placebo (treatment ratio 1.13, 95% CI 1.06–1.21).
- The placebo group improved 8% too, since treadmill testing has a learning effect.
- The semaglutide IQR starts at 0.95, so at least a quarter walked LESS far than at baseline.
- Semaglutide 1.0 mg, everyone had type 2 diabetes, 75% male, median age 68.
- No data on amputation, revascularization or survival.

Peripheral artery disease narrows the arteries in the legs, and its defining symptom is having to stop walking because of pain. Almost nothing improves it. A trial of 792 people measured the thing that matters, **how far they could walk**, and semaglutide beat placebo by 13%.[1] Then look at the spread: at least a quarter of the people on the drug walked less far than when they started.

## Why this endpoint is different

Most of what we cover on this register is a number from a blood test or a scan, standing in for something a person would notice. This is not that. Participants walked on a treadmill at a fixed workload until leg pain stopped them, at the start and again a year later. The endpoint is the distance.

Peripheral artery disease affects an estimated 230 million people, and the treatments that improve how far someone can walk are few. That is why a functional result here counts for more than a laboratory one.

*STRIDE: ratio of maximum walking distance at week 52 to baseline. A ratio above 1.0 means walking further.[1]*

| Group | Median ratio | Interquartile range |
| --- | --- | --- |
| Semaglutide 1.0 mg | 1.21 | **0.95 – 1.55** |
| Placebo | 1.08 | 0.86 – 1.36 |
| **Treatment ratio** | **1.13** | 95% CI 1.06–1.21, p = 0.0004 |

## Two things the headline number hides

The first is that **the placebo group improved too**, by 8%. Repeated treadmill testing has a learning effect, and being in a trial changes how much people walk between visits. So the drug’s own contribution is the 13% difference, not the 21% improvement.

> **The second is in the interquartile range: the semaglutide group’s runs from 0.95 to 1.55.** A ratio below 1.0 means walking a shorter distance than at baseline. At least a quarter of participants taking the drug were worse off at 52 weeks on the measure the trial was built around.

This is not a flaw in the trial. It is what progressive vascular disease looks like, and the placebo group’s lower quartile is worse still, at 0.86. But a median improving while a substantial minority declines is a different picture from “semaglutide improves walking distance,” and it is the picture someone deciding about treatment should have.

> The middle of the group walked further. At least a quarter of them walked less.

## Safety, and what the trial did not ask

Treatment-related serious adverse events were uncommon and slightly more frequent on placebo: six events in five participants on semaglutide against nine in six on placebo. There were no treatment-related deaths. For a 52-week trial in people with a median age of 68 and established vascular disease, that is a reassuring safety picture.

- **The dose was 1.0 mg**, the type 2 diabetes strength, not the 2.4 mg used for weight management.
- **Everyone had type 2 diabetes.** The authors explicitly call for studies in people with peripheral artery disease who do not, which is a large group; [which US indications already apply to them](https://glpwatchdog.org/research/semaglutide-and-peripheral-artery-disease) is a separate question.
- **Three-quarters were men**, and the median age was 68.
- **Nothing here addresses amputation, revascularization or survival**, the outcomes that define how this disease ends. On amputation, the nearest evidence is [a cohort of people with diabetic foot ulcers](https://glpwatchdog.org/research/glp1-diabetic-foot-ulcers-and-perfusion), and it shows an association only.
- **Funded by Novo Nordisk.**

The authors also note that the mechanism is unclear. Whether the benefit comes from weight loss, from improved blood sugar, from effects on the blood vessels themselves, or from something else is unresolved. The broader pattern we have documented is that these drugs’ vascular benefits [do not track weight loss](https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks).

## What it means for someone with claudication

Trial participants had to be able to walk more than 200 meters to enroll (Fontaine stage IIa, the milder end of symptomatic disease). Someone whose walking is more limited than that was not studied.

Within that group, this is real evidence of a functional benefit, in a condition that has very little such evidence. It is a modest benefit, it is not universal, and it sits alongside supervised exercise therapy, which remains the best-established treatment for claudication and was not what this trial compared against.

## Frequently asked questions

### Does semaglutide help peripheral artery disease?

In STRIDE, people with type 2 diabetes and symptomatic peripheral artery disease walked 13% further than those on placebo after 52 weeks, measured on a treadmill. That is a functional benefit rather than a laboratory one, in a condition with few treatments.

### How large is a 13% improvement?

The semaglutide group's walking distance improved by a median of 21% and the placebo group's by 8%, so the drug's own contribution is the 13% difference. Repeated treadmill testing and trial participation both improve walking on their own.

### Did everyone improve?

No. The semaglutide group's interquartile range runs from 0.95 to 1.55, meaning at least a quarter of people taking the drug walked a shorter distance at 52 weeks than at baseline. The placebo group's lower quartile was worse still.

### Does this apply to peripheral artery disease without diabetes?

It has not been tested. Everyone in the trial had type 2 diabetes, and the authors specifically call for studies in people who do not.

### What about amputation or survival?

Not addressed. The trial measured walking distance over 52 weeks and does not speak to the outcomes that define how this disease progresses.

## References

1. Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. The Lancet. 2025. PMID: 40169145. https://pubmed.ncbi.nlm.nih.gov/40169145/

---

Cite as: GLP Watchdog, Nora Bissett, "How Far You Can Walk", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/how-far-you-can-walk

Canonical HTML page: https://glpwatchdog.org/research/how-far-you-can-walk

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
